- Home
- ATGE vs KRYS Comparison
ATGE vs KRYS Comparison
Compare ATGE & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATGE
- KRYS
- Stock Information
- Founded
- ATGE 1987
- KRYS 2015
- Country
- ATGE United States
- KRYS United States
- Employees
- ATGE N/A
- KRYS N/A
- Industry
- ATGE Other Consumer Services
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATGE Consumer Discretionary
- KRYS Health Care
- Exchange
- ATGE Nasdaq
- KRYS Nasdaq
- Market Cap
- ATGE 5.5B
- KRYS 4.7B
- IPO Year
- ATGE 1991
- KRYS 2017
- Fundamental
- Price
- ATGE $144.06
- KRYS N/A
- Analyst Decision
- ATGE Strong Buy
- KRYS Strong Buy
- Analyst Count
- ATGE 3
- KRYS 9
- Target Price
- ATGE $139.00
- KRYS $203.22
- AVG Volume (30 Days)
- ATGE 372.0K
- KRYS 373.9K
- Earning Date
- ATGE 10-30-2025
- KRYS 11-03-2025
- Dividend Yield
- ATGE N/A
- KRYS N/A
- EPS Growth
- ATGE 82.07
- KRYS 36.22
- EPS
- ATGE 6.18
- KRYS 4.91
- Revenue
- ATGE $1,788,290,000.00
- KRYS $359,205,000.00
- Revenue This Year
- ATGE $9.77
- KRYS $34.33
- Revenue Next Year
- ATGE $6.32
- KRYS $47.84
- P/E Ratio
- ATGE $24.21
- KRYS $36.86
- Revenue Growth
- ATGE 12.85
- KRYS 116.08
- 52 Week Low
- ATGE $71.09
- KRYS $122.80
- 52 Week High
- ATGE $155.39
- KRYS $207.84
- Technical
- Relative Strength Index (RSI)
- ATGE 54.44
- KRYS 74.32
- Support Level
- ATGE $147.85
- KRYS $158.08
- Resistance Level
- ATGE $151.36
- KRYS $186.75
- Average True Range (ATR)
- ATGE 3.99
- KRYS 6.01
- MACD
- ATGE -0.53
- KRYS 1.52
- Stochastic Oscillator
- ATGE 40.35
- KRYS 85.15
About ATGE Adtalem Global Education Inc.
Adtalem Global Education Inc is an American for-profit educational company that operates various university and educational programs. The company has three segments namely Chamberlain; Walden; and Medical and Veterinary. It derives maximum revenue from Chamberlain segment.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.